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Yiqi Shexue formula (YQSX) is traditionally used to treat primary immune thrombocytopenia 
(ITP) in clinical practice of traditional Chinese medicine. However, its mechanisms of 
action and molecular targets for treatment of ITP are not clear. The active compounds 
of YQSX were collected and their targets were identified. ITP-related targets were 
obtained by analyzing the differential expressed genes between ITP patients and healthy 
individuals. Protein–protein interaction (PPI) data were then obtained and PPI networks 
of YQSX putative targets and ITP-related targets were visualized and merged to identify 
the candidate targets for YQSX against ITP. Gene ontology and Kyoto Encyclopedia of 
Genes and Genomes pathway analysis were carried out. The gene-pathway network 
was constructed to screen the key target genes. In total, 177 active compounds and 
251 targets of YQSX were identified. Two hundred and thirty differential expressed genes 
with an P value < 0.005 and |log2(fold change)| > 1 were identified between ITP patient 
and control groups. One hundred and eighty-three target genes associated with ITP 
were finally identified. The functional annotations of target genes were found to be related 
to transcription, cytosol, protein binding, and so on. Twenty-four pathways including 
cell cycle, estrogen signaling pathway, and MAPK signaling pathway were significantly 
enriched. MDM2 was the core gene and other several genes including TP53, MAPK1, 
CDKN1A, MYC, and DDX5 were the key gens in the gene-pathway network of YQSX 
for treatment of ITP. The results indicated that YQSX’s effects against ITP may relate to 
regulation of immunological function through the specific biological processes and the 
related pathways. This study demonstrates the application of network pharmacology in 
evaluating mechanisms of action and molecular targets of complex herbal formulations.
Keywords: Yiqi Shexue formula, primary immune thrombocytopenia, network pharmacology, mechanism, target 
gene, pathway
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INTrODUcTION
Primary immune thrombocytopenia (ITP) is the most common 
autoimmune cytopenia characterized by transient or persistent 
decreased platelet count (Comont et al., 2017; Castro, 2017). The 
occurrence of ITP results from the generation of anti-platelet 
autoantibodies against platelet membrane glycoproteins finally 
leading to the destruction of platelets in the reticuloendothelial 
system, especially in the spleen (Zhang et al., 2015). ITP patients 
have an increased risk of bruising, cutaneous bleeding, and 
infrequently serious bleeding including intracranial hemorrhage 
(Lin et al., 2017). In addition, the quality of life of ITP patients is 
affected as a result of the physical and psychological symptoms, 
discomfort, fear, reduced social activity, and reduced ability 
to work (López et al., 2015). The standard therapy for newly 
diagnosed ITP patients is to stop bleeding and increase platelet 
counts using pharmaceutical medicines (Kühne, 2015). However, 
these treatments are often accompanied by harmful side effects, 
which tend to be more evident with the time of treatment. In 
addition, the high treatment costs cast a heavy financial burden 
to ITP patients, especially those with severe forms of the disease 
(Khellaf et al., 2011).
In recent years, traditional Chinese medicine (TCM) has 
been regarded as a potential effective auxiliary strategy to treat 
the chronic diseases, including ITP (He et al., 2015). Huang et 
al. (2013) reported that a modified Chinese herbal formula, 
Zi-Ying-Jiang-Huo-Tang (Phellodendri Combination) cured 
a 4-year-old ITP patient who did not respond to a 7-month 
first-line conventional treatment of steroids and intravenous 
immunoglobulin, and no recurrence of the disease or side 
effects of the treatment were found during the 12-month 
follow-up period. Yang et al. (2017) reported that imbalance 
of Th1/Th2 and Th17/Treg cells play a crucial role in the 
pathogenesis of chronic ITP and that Yiqi Tongyang Decoction 
significantly regulated the dynamics of Th1/Th2 and Th17/
Treg equilibria.
Yiqi Shexue formula (YQSX), an improved formula of 
Bazhen decoction (BZD), is a mixture of 9 Chinese medicine 
extracts including Ginseng Radix et Rhizoma (GRR, the dried 
root and rhizome of Panax ginseng C. A. Mey.), Poria [P, the 
dried sclerotium of Poria cocos (Schw.) Wolf], Atractylodis 
Macrocephalae Rhizoma (AMR, the dried rhizome of 
Atractylodes macrocephala Koidz.), Glycyrrhizae Radix et 
Rhizoma (RRG, the dried root and rhizome of Glycyrrhiza 
uralensis Fisch), Angelicae Sinensis Radix [ASR, the dried 
root of Angelica sinensis (Oliv.) Diels], Chuanxiong Rhizoma 
(CR, the dried rhizome of Ligusticum chuanxiong Hort.), 
Paeoniae Radix Alba (PRA, the dried root of Paeonia lactiflora 
Pall.), Rehmanniae Radix Praeparata (RRP, the dried root of 
Rehmannia glutinosa Libosch.), and Asini Corii Colla (ACC, 
the product of hide of Equus asinus L.). In TCM, BZD is 
frequently used to treat the deficiency of qi and blood which is 
characterized by many symptoms, including anemia, asthenia, 
dizziness, chronic abscess, fatigue, irregular menstruation, 
palpitations, fatigue of the muscles, and pale complexion (Song 
et al., 2014). It has been reported that BZD could substantially 
promote the proliferation of bone marrow hematopoietic 
cells in anemic mice (Tian et al., 2016). YQSX is formulated 
based on BZD with one additional medicine (ACC). ACC is 
obtained from Equus asinus Linnaeus and has been widely 
used to promote health in China for life cultivation and 
clinical hematic antanemic therapy as a health food and TCM 
for more than 2,000 years. And early evidence has shown 
that ACC possesses a therapeutic effect in treating various 
hematologic diseases, such as anemia, aleucocytosis, and 
thrombopenia (Wang et al., 2014). In TCM, YQSX has been 
suggested to be able to invigorate spleen, replenish qi, nourish 
blood, and promote blood circulation and is traditionally used 
to treat ITP in clinical practice. However, the mechanisms of 
action and molecular targets of YQSX for treatment of ITP are 
not clear, which is the main factor limiting its wider use.
In TCM, complex herbal formulations that consist of 
multiple herbs are used and these complex chemical mixtures 
include numerous potential bioactive components that 
can interact with multiple therapeutic targets. This multi-
component, multi-target, and multi-pathway approach 
may be ideal for the treatment of diseases with complex 
pathophysiology and therapeutic targets, but also present a 
tremendous challenge in understanding of the interactions 
between various components, their mechanisms of action 
and molecular targets. Liu et al. (2016) proposed the 
concept of Network Pharmacology in an attempt to solve 
these problems. Network pharmacology is a novel approach 
that combines system network analysis and pharmacology. 
It could be used to elucidate the synergistic effects among 
compounds and potential mechanisms of multi-component 
and multiple target drugs at the molecular level through the 
networks of compound–compound, compound–target, and 
target–disease. Network pharmacology would facilitate the 
understanding of the interactions among the compounds, 
genes, proteins, and diseases and is suitable for the study of 
complex TCM formulations (Xu et al., 2017; Zeng et al., 2017). 
Chen et al. (2018) explored potential mechanism of Jiawei 
Foshou San on endometriosis using a network pharmacology 
approach. The underlying action mechanism of Wu-Tou 
decoction in rheumatoid arthritis was expounded by network 
pharmacology prediction and experimental verification (Guo 
et  al., 2017). The potential mechanism between Danggui-
shaoyao-san and neurodegenerative disorders was deciphered 
through a network pharmacology approach (Luo et al., 2016). 
The research group of Shao Li elucidated anti-rheumatic 
mechanisms of Qing-Luo-Yin and investigated its possible 
interactions with methotrexate using an integrating strategy 
coupled with network pharmacology and metabolomics 
techniques (Zou et al., 2018).
In the present study, a network pharmacology approach 
was used to explore the mechanisms of action and molecular 
targets of YQSX for treatment of ITP. The active compounds 
of YQSX and their targets were firstly identified using 
drugbank database. Then ITP-related targets were obtained 
by analyzing the differential expressed genes between ITP 
patients and healthy individuals. The mechanisms of action 
underlying YQSX for the treatment of ITP were analyzed by 
gene ontology (GO) and pathway analysis.
Frontiers in Pharmacology | www.frontiersin.org October 2019 | Volume 10 | Article 1136




We identified the chemical composition of YQSX from Traditional 
Chinese Medicine Systems Pharmacology Database and Analysis 
Platform (Ru et al., 2014) (TCMSP, http://lsp.nwu.edu.cn/
tcmsp.php) and select candidate compounds which has oral 
bioavailability (OB) ≥ 30% and drug-likeness (DL) ≥ 0.18 (Li et al., 
2015). One hundred and sixty eligible compounds were obtained, 
22 in GRR, 15 in P, 7 in AMR, 92 in RRG, 2 in ASR, 7 in CR, 13 in 
PRA, and 2 in RRP. However, 8 compounds including ferulic acid, 
ligustilide, senkyunolide C, and leonuride which were not found in 
the database have been selected as they have the pharmacological 
activity on ITP treatment. Additionally, 19 amino acids including 
aspartic acid, threonine, and serine in ACC have been reported 
to process relevant pharmacological properties and were also 
included (Wang et al., 2014). Eventually, 177 candidate compounds 
were obtained in total after the duplications were removed.
Identification of Potential Targets
The 177 candidate compounds were imported into the DrugBank 
database (Law et al., 2014) (https://www.drugbank.ca/) to 
identify the corresponding targets of YQSX. One hundred and 
forty-eight compounds were finally selected after removing 29 
compounds which did not link to any targets. And the targets 
of 148 compounds were collected. Two thousand one hundred 
and seventy-seven targets were identified, 204 in GRR, 28 in P, 
20 in AMR, 1272 in RRG, 106 in ASR, 36 in CR, 99 in PRA, 58 in 
RRP, and 354 in ACC. A total of 251 targets were collected after 
removing duplication.
ITP-related Targets
The differential expressed genes of ITP patients were obtained 
from GEO database (https://www.ncbi.nlm.nih.gov/geo/, Series: 
GSE574, Samples: GSM8814, GSM8815, GSM8816, GSM8817). 
Genes with a P value < 0.005 and |log 2(fold change)| > 1 were 
considered to be of significantly differential expression and ITP-
related targets.
Network construction
The compound-target network of YQSX was constructed and 
visualized using Cytoscape 3.5.1 software. PPI data were obtained 
from Database of Interacting Proteins (DIP™), Biological General 
Repository for Interaction Datasets (BioGRID), Human Protein 
Reference Database (HPRD), IntAct Molecular Interaction 
Database (IntAct), Molecular INTeraction database (MINT), 
and biomolecular interaction network database (BIND) using 
the plugin Bisogenet (Martin et al., 2010) of Cytoscape 3.5.1 
software. The PPI networks of YQSX putative targets and ITP-
related targets were visualized with Cytoscape software.
Network Merge
The PPI networks of YQSX putative targets and ITP-related 
targets were merged with Cytoscape software. And the nodes with 
topological importance in the interaction network were screened 
by calculating Degree Centrality (DC), Betweenness Centrality 
(BC), Closeness Centrality (CC), Eigenvector Centrality (EC), 
Local average connectivity-based method (LAC), and Network 
Centrality (NC) with the Cytoscape plugin CytoNCA. These 
parameters represent the topological importance and they have 
been reported about their definitions and computational formulas 
and used in network pharmacology and systems pharmacology 
(Tang et al., 2015).
Bioinformatic analysis
GO analysis with the biological process, cellular component, 
and molecular function was carried out using the Database for 
Annotation, Visualization and Integrated Discovery (DAVID, 
https://david.ncifcrf.gov, v6.8) (Huang et al., 2009). Functional 
categories were enriched within genes (FDR < 0.05) and the 
top 20 GO functional categories were selected. DAVID that 
assigned Kyoto Encyclopedia of Genes and Genomes (KEGG) 
database was used for pathway analysis. Pathways that had 
significant changes of FDR < 0.05 were identified for further 
analysis. The genes that significantly regulated pathways were 
selected for gene-pathway network analysis. The gene-pathway 




One hundred and forty-eight compounds of YQSX (Table 1) 
were finally selected as the candidate compounds. And 230 ITP-
related targets were identified from GEO database. As shown in 
Figure 1, a volcano plot was created to show the distribution of 
differentially expressed genes, which were represented by the red 
dots in the plot.
The Compound-target network of YQSX was constructed 
using the screened compounds and their targets as shown in 
Figure 2. The network contained 399 nods (148 compounds 
in YQSX and 251 compound targets) and 2,177 edges which 
indicated the compound-target interactions. One hundred 
and forty-eight candidate compounds had a median of 12 
degrees, which suggested that most compounds of YQSX 
affected multiple targets. Kaempferol, glycine, and stigmasterol 
acted on 118, 99 and 87 targets, respectively. And the OB of 
kaempferol, glycine, and stigmasterol is 41.88, 48.74, and 
43.83%, respectively. Therefore, they might be the crucial 
active compounds of YQSX by reason of their considerable 
positioning in the network.
PPI Networks analysis
PPI operates large-scale biological processes, such as cell-to-cell 
interactions, metabolic control, and developmental control, and is 
increasingly regarded as the primary objectives of system biology 
(Rao et al., 2014). Therefore, PPI networks of YQSX putative 
targets and ITP-related targets were visualized using PPI data. 
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TaBlE 1 | The final selected compounds in YQSX for analysis.
ID Name OB Dl Source ID Name OB Dl Source
MOL000449 Stigmasterol 43.83 0.76 GRR, ASR, RRP MOL004908 1,3-dihydroxy-8,9-dimethoxy-6-
benzofurano[3,2-c]chromenone
62.9 0.53 RRG
MOL000358 β-sitosterol 36.91 0.75 GRR, ASR, PRA MOL004910 (2R)-7-hydroxy-2-(4-
hydroxyphenyl)chroman-4-one
71.12 0.18 RRG
MOL003648 Inermin 65.83 0.54 GRR MOL004911 Glabrene 46.27 0.44 RRG
MOL005317 Deoxyharringtonine 39.27 0.81 GRR MOL004912 Glabrone 52.51 0.5 RRG
MOL005320 Arachidonate 45.57 0.2 GRR MOL004913 Hedysarimcoumestan B 48.14 0.43 RRG
MOL005321 Frutinone A 65.9 0.34 GRR MOL004914 Glabridin 53.25 0.47 RRG
MOL005356 Girinimbine 61.22 0.31 GRR MOL004915 Eurycarpin A 43.28 0.37 RRG
MOL005376 Panaxadiol 33.09 0.79 GRR MOL004924 (-)-Medicocarpin 40.99 0.95 RRG
MOL005384 Suchilactone 57.52 0.56 GRR MOL004935 Sigmoidin B 34.88 0.41 RRG
MOL000787 Fumarine 59.26 0.83 GRR MOL004941 Glabranin 52.9 0.31 RRG
MOL002879 Diop 43.59 0.39 GRR MOL004945 Isobavachin 36.57 0.32 RRG
MOL000422 Kaempferol 41.88 0.24 GRR, PRA, RRG MOL004948 Isoglycyrol 44.7 0.84 RRG
MOL005308 Aposiopolamine 66.65 0.22 GRR MOL004949 Isolicoflavonol 45.17 0.42 RRG
MOL005344 Ginsenoside Rh2 36.32 0.56 GRR MOL004957 Isoformononetin 38.37 0.21 RRG
MOL005348 Ginsenoside Rh4 31.11 0.78 GRR MOL001484 Inermine 75.18 0.54 RRG
MOL005318 Dianthramine 40.45 0.2 GRR MOL004959 1-Methoxyphaseollidin 69.98 0.64 RRG
MOL005399 Daucosterol 36.91 0.75 GRR MOL004993 8-prenylated eriodictyol 53.79 0.4 RRG
MOL000676 Dibutyl Phthalate 64.54 0.13 GRR, PRA MOL004961 Quercetin der. 46.45 0.33 RRG
MOL000273 (3β,16α)-3,16-Dihydroxylanosta-
7,9(11),24-trien-21-oic acid
30.93 0.81 P MOL004966 7,2′,4′-trihydroxy-5-methoxy-3-
arylcoumarin
83.71 0.27 RRG
MOL000275 Trametenolic acid 38.71 0.8 P MOL000497 Licochalcone A 40.79 0.29 RRG
MOL000279 Cerevisterol 37.96 0.77 P MOL004974 3′-Methoxyglabridin 46.16 0.57 RRG
MOL000282 Stellasterol 43.51 0.72 P MOL004978 4′-Methoxyglabridin 36.21 0.52 RRG
MOL000283 Ergosterol peroxide 40.36 0.81 P MOL004980 Inflacoumarin A 39.71 0.33 RRG
MOL000296 Hederagenin 36.91 0.75 P MOL004985 Icos-5-enoic acid 30.7 0.2 RRG
MOL000022 14-acetyl-12-senecioyl-2E,8Z, 
10E-atractylentriol












MOL000049 3β-acetoxyatractylone 54.07 0.22 AMR MOL004990 3′-Hydroxy-4′-O-Methylglabridin 43.71 0.57 RRG
MOL000072 8β-ethoxy atractylenolide III 35.95 0.21 AMR MOL004991 7-Acetoxy-2-methylisoflavone 38.92 0.26 RRG
MOL001792 Liquiritigenin 32.76 0.18 RRG MOL004996 Gadelaidic acid 30.7 0.2 RRG
MOL000211 Mairin 55.38 0.78 RRG, PRA MOL000500 Vestitol 74.66 0.21 RRG
MOL002311 Glycyrol 90.78 0.67 RRG MOL005000 Gancaonin G 60.44 0.39 RRG
MOL000239 Jaranol 50.83 0.29 RRG MOL005001 Gancaonin H 50.1 0.78 RRG
MOL002565 Medicarpin 49.22 0.34 RRG MOL005003 Licoagrocarpin 58.81 0.58 RRG
MOL000354 Isorhamnetin 49.6 0.31 RRG MOL005007 Glyasperins M 72.67 0.59 RRG
MOL000359 Sitosterol 36.91 0.75 RRG, CR, RRP, PRA MOL005008 Glycyrrhiza flavonol A 41.28 0.6 RRG
MOL003656 Lupiwighteone 51.64 0.37 RRG MOL005012 Licoagroisoflavone 57.28 0.49 RRG
MOL003896 7-Methoxy-2-methyl isoflavone 42.56 0.2 RRG MOL005016 Odoratin 49.95 0.3 RRG
MOL000392 Formononetin 69.67 0.21 RRG MOL005017 Phaseol 78.77 0.58 RRG
MOL000417 Calycosin 47.75 0.24 RRG MOL005018 Xambioona 54.85 0.87 RRG
MOL004328 Naringenin 59.29 0.21 RRG MOL005020 Dehydroglyasperins C 53.82 0.37 RRG
MOL004805 Shinflavanone 31.79 0.72 RRG MOL000098 Quercetin 46.43 0.28 RRG
MOL004806 Euchrenone 30.29 0.57 RRG MOL000360 Ferulic acid 39.56 0.06 ASR, CR
MOL004808 Glyasperin B 65.22 0.44 RRG MOL011782 Ligustilide 23.5 0.07 ASR, CR
MOL004810 Glyasperin F 75.84 0.54 RRG MOL002143 Senkyunolide-C 46.8 0.08 ASR, CR
MOL004811 Glyasperin C 45.56 0.4 RRG MOL002111 3-Butylidenephthalide 42.44 0.07 ASR, CR
MOL004814 Isotrifoliol 31.94 0.42 RRG MOL001494 Mandenol 42 0.19 CR
MOL004815 Kanzonol B 39.62 0.35 RRG MOL002135 Myricanone 40.6 0.51 CR
MOL004820 Kanzonol W 50.48 0.52 RRG MOL002140 Perlolyrine 65.95 0.27 CR
MOL004824 6-prenylated eriodictyol 39.22 0.41 RRG MOL002157 Wallichilide 42.31 0.71 CR
MOL004827 Semilicoisoflavone B 48.78 0.55 RRG MOL000433 Folic Acid 68.96 0.71 CR
MOL004828 Glepidotin A 44.72 0.35 RRG MOL001918 Paeoniflorigenone 87.59 0.37 PRA
MOL004829 Glepidotin B 64.46 0.34 RRG MOL001919 Palbinone 43.56 0.53 PRA
MOL004833 Phaseolinisoflavan 32.01 0.45 RRG MOL001924 paeoniflorin 53.87 0.79 PRA
MOL004835 Glypallichalcone 61.6 0.19 RRG MOL000492 Cianidanol 54.83 0.24 PRA
(Continued)
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The PPI network of YQSX putative targets contained 5,959 nodes 
and 148,332 edges, which represented 5,959 interacting protein 
and 148,332 interactions. The PPI network of ITP-related targets 
contained 5,163 nodes and 127,564 edges.
Identification of candidate Targets for 
YQSX against ITP
In order to reveal the mechanisms of action underling YQSX’s 
effects on ITP, the PPI network of YQSX putative targets and the 
PPI network of ITP-related targets were merged to identify the 
candidate targets for YQSX against ITP. This network consisting 
of 3,232 nodes and 95,775 edges was presented in Figure 3A. 
The median degree of all nodes was 37 and the nodes with more 
than 74 degrees were identified as significant targets according 
to the previous research (Zhang et al., 2013). A network of 
significant targets for YQSX against ITP was constructed and it 
contained 780 nodes and 35,907 edges (Figure 3B). The median 
values of DC, BC, CC, EC, LAC, and NC were 117, 6,403.125, 
0.318309, 0.024411, 19.61376, and 27.984, respectively. The 
candidate targets were further screened and 183 targets with 
DC > 117, BC > 6,403.125, CC > 0.318309, EC > 0.024411, 
LAC > 19.61376, and NC > 27.984 were identified (Figure 3C). 
One hundred and eighty-three target genes were eventually 
identified for YQSX against ITP.
gO and Pathway Enrichment analysis
DAVID was used to perform GO and KEGG pathway analysis of the 
183 candidate targets identified. GO of candidate targets was analyzed 
based on biological process, cellular component, and molecular 
function. One hundred seventy-two GO terms were significantly 
enriched (FDR < 0.05), 98 in biological process, 29 in cellular 
component, and 45 in molecular function. The data of GO analysis 
were shown in Supplementary Table 1. Top 20 terms were shown 
in Figure 4. The highly enriched GO terms in biological process, 
cellular component, and molecular function included regulation of 
gene silencing, regulation of gene expression, nucleoplasm, nucleus, 
protein binding, and ubiquitin protein ligase binding.
The pathways that were significantly influenced by YQSX in the 
process of treating ITP were identified by KEGG pathway analysis. 
Twenty-four significantly enriched pathways (FDR < 0.05) including 
Epstein-Barr virus infection, cell cycle, estrogen signaling pathway, 
pathway in cancer, and MAPK signaling pathway were identified. 
FIgUrE 1 | Volcano plot of differentially expressed genes. The abscissa 
represents the fold changes in gene expression and the ordinate represents 
the statistical significance of the variations in gene expression. The red dots 
represent significantly differentially expressed genes.
TaBlE 1 | Continued
ID Name OB Dl Source ID Name OB Dl Source
MOL004838 Glabrocoumarone A 58.44 0.38 RRG MOL000748 5-(Hydroxymethyl)-2-furaldehyde 45.07 0.02 RRP
MOL004841 Licochalcone B 76.76 0.19 RRG MOL001436 Leonuride 2.6 0.33 RRP
MOL004848 Licochalcone G 49.25 0.32 RRG MOL002819 Catalpol 5.07 0.44 RRP
MOL004849 Licoarylcoumarin 59.62 0.43 RRG MOL000067 Valine 53.33 0.01 ACC
MOL004855 Licoricone 63.58 0.47 RRG MOL007579 Hydroxyproline 83.55 0.02 ACC
MOL004856 Gancaonin A 51.08 0.4 RRG MOL000061 Proline 77.57 0.01 ACC
MOL004857 Gancaonin B 48.79 0.45 RRG MOL000050 Glycine 48.74 0 ACC
MOL004863 Gancaonin L 66.37 0.41 RRG MOL000071 Histidine 53.18 0.03 ACC
MOL004864 Gancaonin M 30.49 0.41 RRG MOL000054 Arginine 47.64 0.03 ACC
MOL004866 Gancaonin O 44.15 0.41 RRG MOL003971 Threonine 73.52 0.01 ACC
MOL004879 Glycyrin 52.61 0.47 RRG MOL003969 Serine 98.5 0.01 ACC
MOL004882 Licocoumarone 33.21 0.36 RRG MOL000052 Glutamic Acid 6.66 0.02 ACC
MOL004883 Licoisoflavone 41.61 0.42 RRG MOL000042 Alanine 87.69 0.01 ACC
MOL004884 Licoisoflavone B 38.93 0.55 RRG MOL005449 Methionine 70.87 0.01 ACC
MOL004885 Licoisoflavanone 52.47 0.54 RRG MOL005448 Leucine 72.92 0.01 ACC
MOL004891 Shinpterocarpin 80.3 0.73 RRG MOL000068 Isoleucine 59.05 0.02 ACC
MOL004898 5-Prenylbutein 46.27 0.31 RRG MOL000056 Tyrosine 57.55 0.05 ACC
MOL004903 Liquiritin 65.69 0.74 RRG MOL000041 Phenylalanine 41.62 0.04 ACC
MOL004904 Licopyranocoumarin 80.36 0.65 RRG MOL000065 Aspartic Acid 79.74 0.02 ACC
MOL004907 Glyzaglabrin 61.07 0.35 RRG MOL001780 Tryptophane 75.93 0.08 ACC
OB, oral bioavailability; DL, drug-likeness; GRR, Ginseng Radix et Rhizoma; P, Poria; AMR, Atractylodis Macrocephalae Rhizoma; RRG, Glycyrrhizae Radix et Rhizoma; ASR, 
Angelicae Sinensis Radix; CR, Chuanxiong Rhizoma; PRA, Paeoniae Radix Alba; RRP, Rehmanniae Radix Praeparata; ACC, Asini Corii Colla.
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FIgUrE 3 | Identification of candidate targets of YQSX against ITP. (a) The interactive PPI network of YQSX putative targets and ITP-related targets. (B) PPI network 
of significant proteins extracted from A. (c) PPI network of candidate YQSX targets for ITP treatment extracted from B. DC, degree centrality; BC, betweenness 
centrality; CC, closeness centrality; EC, eigenvector centrality; LAC, local average connectivity-based method; NC, network centrality.
FIgUrE 2 | Compound- target network of YQSX. The blue triangles represent targets; the yellow, pink, cyan, kelly green, green, orange, red, gray, and violet ovals 
represent the compounds from GRR, P, AMR, RRG, ASR, CR, PRA, RRP, and ACC, respectively.
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FIgUrE 4 | Gene ontology terms of candidate targets of YQSX against ITP. The top 20 GO functional categories with FDR < 0.05 were selected.
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The data of KEGG pathway analysis were shown in Supplementary 
Table 2. As shown in Figure 5, size of the spot represented number 
of genes and color represented FDR value.
gene-Pathway Network analysis
The gene-pathway network was constructed based on the 
significantly enriched pathways and genes that regulated these 
pathways, which was presented in Figure 6. The topological 
analysis of 24 pathways and 115 genes was carried out with 
BC. The squares represented target genes and the V-shapes 
represented pathways in the network. The network diagram 
suggested that MDM2 had the most maximum BC and was 
the core target gene. Other several genes also had larger BC, 
such as TP53, MAPK1, CDKN1A, MYC, and DDX5. They 
might be the key target gens for YQSX against ITP.
DIScUSSION
The unique medical theory of TCM has been formed and 
developed over thousands of years in China for the treatment 
and preventions of diseases. Multiple compatible herbs are 
usually used as complex herbal formulations to improve 
therapeutic effect through synergism (Li et al., 2016). In TCM, 
ITP is thought to be a disease caused by the failure of spleen 
to manage blood. Guipi decoction and BZD were the most 
common prescribed formulas in the treatment of ITP in TCM. 
YQSX, the improved formula of BZD, is an empirical formula 
to treat ITP in TCM clinical practice, and has demonstrated 
significant clinical effects. Compared with BZD, ACC is 
added to YQSX. ACC has been shown to enrich the blood and 
to improve hemorheology, hemostasis, and immunological 
regulation, and its addition has further strengthened the BZD’s 
FIgUrE 5 | KEGG pathway enrichment of candidate targets of YQSX against ITP. Pathways that had significant changes of FDR <0.05 were identified. Size of the 
spot represents number of genes and color represents FDR value.
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effects for the treatment of ITP. TCM adopts a holistic approach 
focusing on overall functional recovery and elimination of the 
cause of the disease. The concept of network pharmacology is 
comparable to TCM theory and is therefore appropriate to be 
used for the research on unknown components and mechanism 
of action of complex TCM herbal formulations supported by a 
variety of databases and software available.
In the present study, a compound-target network of YQSX 
was constructed using the 148 compounds and 251 compound 
targets. The results suggested that most compounds of 
YQSX affected multiple targets, for example, kaempferol, 
glycine, and stigmasterol acted on 118, 99, and 87 targets, 
respectively. Therefore, they were very likely to be the crucial 
pleiotropically active compounds for YQSX. Although the 
number of putative targets in each single herb was different, 
the overlapping targets in different herbs were numerous. 
In another word, multiple compounds of YQSX may have 
the same target providing synergistic effects. Kaempferol 
is a representative flavonoid and has been shown to exert 
multiple pharmacological activities, such as antioxidant, anti-
inflammatory, anti-cancer, anti-diabetic, anti-osteoarthritic, 
and immunomodulatory properties (Tsai et al., 2018; Wang 
et al., 2018). Lin et al. (2011) reported that kaempferol 
might be a potent immunosuppressant to decrease the 
harmful immune responses, including chronic inflammation 
and autoimmunity. Glycine is an important amino acid 
contributing to metabolism, growth, development, immunity, 
cytoprotection, and survival owning to its anti-inflammatory 
and immunomodulatory properties (Lu et al., 2017; 
Heidari et al., 2018). Stigmasterol also showed anti-cancer, 
FIgUrE 6 | Gene-Pathway Network of YQSX against ITP. The topological analysis of 24 pathways and 115 genes was carried out with betweenness centrality. The 
yellow squares represent target genes and the red V-shapes represent pathways. Big size represents the larger betweenness centrality.
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anti-inflammatory and anti-allergic properties as well as the 
modulatory effects on immune responses (Antwi et al., 2017). 
TCM is a highly complex system and contains a large number 
of constituents. Researchers try to verify even more effective 
chemical components from TCM through various approaches 
including network pharmacology. But there has not been a 
way to recognize the total effective constituents of TCM up 
till the present moment. It is well known that the effects of 
TCM on treating diseases are the result of the combination 
effects of many constituents. In the present study, kaempferol, 
glycine, and stigmasterol regulated the most targets associated 
with ITP and all of them have immunomodulatory properties. 
Although kaempferol, glycine, and stigmasterol are ubiquitous 
and widely known compounds, there is some evidence for 
their immunomodulatory effects. In addition, they have high 
oral bioavailability and kaempferol and stigmasterol came 
from 3 herbs of YQSX. Therefore, they might be identified as 
the representative compounds for YQSX.
The PPI networks of YQSX putative targets and ITP-related 
targets were structured and merged to obtain the candidate targets 
for YQSX against ITP. In order to get the more accurate targets, 
6 parameters including DC, BC, and CC were set to screen 
nodes and structure a new network. One hundred and eighty-
three targets were finally identified and used to carry out the 
bioinformatic analysis to elucidate the mechanisms underlying 
the anti-ITP effects of YQSX.
The targets of YQSX against ITP were enriched in biological 
processes, cellular components, and molecular function by GO 
enrichment analysis. Results suggested that YQSX regulated 
some biological processes, such as gene silencing, gene 
expression, apoptotic process, and signal transduction by p53 
class mediator. ITP is an autoimmune disease characterized by 
an abnormality in T cell immunity and T cell mechanism has 
been proved to be an important pathophysiologic mechanism 
in ITP (Jernås et al., 2013; Ji et al., 2014). It has been shown 
that allogenic T cell responses could be inhibited through the 
production of immunoregulatory dendritic cells resulted by 
silencing RelB (Zhang et al., 2010). The expression of CD72 
and IL-2 was decreased whilst the IFN-γ/IL-4 expression was 
increased in ITP patients (Zhou et al., 2012). Apoptotic process 
plays an important role in maintenance of normal immune 
system development, and a failure of apoptotic function has 
been shown to be associated with the pathogenesis of ITP 
(Qian et al., 2018). It has been found that mesenchymal 
stem cells from ITP patients showed increased apoptosis and 
a defect in immunoregulation and the apoptotic rate was 
decreased by inhibiting the expression of p53 (Zhang et  al., 
2016). Therefore, YQSX may help to regulate immunological 
function through intervening these biological/pathological 
processes. It has been suggested that the pathogenesis of ITP 
was associated with gene expression, regulation of apoptosis, 
regulation of cell proliferation, nucleoplasm, transcription 
factor binding, histone deacetylase binding, protein kinase 
binding, and core promoter binding (Deng et al., 2017; Zuo 
et al., 2017), all of which were significantly enriched in the 
present study. Therefore, YQSX may exert regulatory function 
in the pathogenesis of ITP and may also affect some cellular 
components and molecular function including nucleoplasm, 
nucleus, cytosol, protein binding, enzyme binding, and 
DNA binding in the treatment of ITP. Studies have found 
that the ultrastructural abnormalities in cytoplasmic 
vacuolization, mitochondrial swelling, abnormal chromatin 
condensation, and increased staining for activated caspase-3 
in megakaryocytes also occur in ITP patients (Kistanguri and 
McCrae, 2013).
TCM is multi-component, multi-target, and multi-
pathway. YQSX, as a TCM formula, also has the same 
characteristic. Therefore, it can be sure that YQSX treats 
ITP through multi-pathway. In the present study, a total of 
24 KEGG pathways including MAPK signaling pathway and 
PI3K-AKT signaling pathway were significantly enriched. 
MAPKs can regulate gene expression, immune response, 
cell proliferation, apoptosis, and response to oxidative stress, 
which is one of the mechanisms of immune regulation (Li 
et al., 2017). Research suggested that PI3K-AKT signaling 
pathways played a role in reducing excessive innate immune 
responses and crosstalk between MAPK, which was one of the 
mechanisms to balance the innate immune responses (Rohani 
et al., 2010). Eltrombopag is a thrombopoietin receptor 
agonist and has been used to treat the thrombocytopenia 
of ITP. The signaling mechanisms of eltrombopag are 
involved in AKT and MAPK pathways, which is similar to 
that of thrombopoietin (Kim et al., 2018). Therefore, YQSX 
may regulate immunological function through the related 
pathways in the process of ITP treatment. In this study, several 
pathways related to viral also were significantly enriched. 
The viral infection relates to the genesis of ITP. The body’s 
autoimmune response is activated when infected with virus, 
such as Human Immunodeficiency Virus, Hepatitis C Virus, 
Epstein-Barr virus, Cytomegalovirus, Herpes simplex virus, 
and Varicella zoster virus, and the autoimmune response will 
perpetuate itself despite viral clearance (Audia et al., 2017). 
The autoimmune response triggered by viral infection might 
be regulated by YQSX through specific pathways, such as 
Epstein-Barr virus infection, viral carcinogenesis, Hepatitis 
B, HTLV-I infection, and Herpes simplex infection. In a 
human study, plasma samples from 74 ITP patients and 58 
healthy controls were collected and bioinformatic analysis was 
carried out. The results indicated that the occurrence of ITP 
was associated with proteoglycans in cancer, prostate cancer, 
glioma, thyroid hormone signaling pathway, and estrogen 
signaling pathway (Zuo et al., 2017). In the present study, the 
aforementioned pathways were also significantly enriched, 
which suggested that the regulation of pathways associated 
with the occurrence of ITP might be one of the mechanisms 
of YQSX for treatment of ITP. In addition, YQSX may 
function by regulating other pathways, including cell cycle, 
and neurotrophin and ErbB signaling pathways. Inhibition 
of cell cycle caused by selective inhibition of lymphocyte 
proliferation was found to be beneficial for treating refractory 
ITP (Grace and Neunert, 2016).
Gene-pathway network was constructed to investigate the core 
and key target genes for YQSX against ITP. Results suggested that 
MDM2 had the maximum BC and it might be the core target 
Frontiers in Pharmacology | www.frontiersin.org October 2019 | Volume 10 | Article 1136
Mechanisms of Yiqi Shexue for Treatment of ITPJiang et al.
11
gene. Other top 5 genes (TP53, MAPK1, CDKN1A, MYC, and 
DDX5) were selected as the key target gens. MDM2 can negatively 
regulate p53 which is a central cell cycle regulator and has a 
negatively regulatory effect on autoimmunity (Liu et al., 2017). 
MDM2 can block the transactivation domain of p53 and affects 
gene transcription by inhibiting the ability and then block the 
progression of cell cycle and promote apoptosis (Wang et al., 2012). 
MDM2 can regulate a functional autologous immune response; 
therefore, it is linked to the development of autoimmunity (Mayr 
et al., 2006). Studies on the role of MDM2 in immune regulation 
illustrated that inhibition of MDM2 promoted T cell proliferation 
induced by dendritic cells (Gasparini et al., 2012). It is well-known 
that MAPKs are an essential regulator of immune responses. The 
TP53 gene provides instructions to make the p53 protein (Vickers, 
2018). The expression and stability of p53 can be promoted by 
inhibiting PKA and p53 phosphorylation inactivates BCL-XL, 
leading to platelet apoptosis (Zhao et al., 2017). Research found 
that CDKN1A has a potential pro-apoptotic effect by reason of 
arresting cells at G1 or G2/M phases (Hui et al., 2014). CDKN1A 
protein is also a p53 transcriptional target and can activate cell 
cycle checkpoints, promote DNA repair, downregulate apoptosis, 
and trigger a senescence-like growth arrested response, all of 
which play an important role in the network of DNA damage 
surveillance (Mirzayans and Murray, 2016). MYC has been 
suggested to directly coordinate the immune response through 
regulating the immune checkpoints expression (Casey et al., 2017). 
It has been widely accepted that the role of Th17 cells in ITP is a 
possible pathogenic factor and a potential therapeutic target of ITP 
(Ye et al., 2015). DDX5 was found to control the differentiation of 
Th17 cells at steady state and autoimmunity (Huang et al., 2015).
The mechanisms of action and molecular targets of YQSX 
for ITP were explored using a network pharmacology approach 
in this study. Kaempferol, glycine, and stigmasterol regulated 
the most targets associated with ITP. YQSX may regulate 
immunological function through the specific biological 
processes including gene silencing, gene expression, apoptotic 
process, and signal transduction by p53 class mediator and 
the related pathways including MAPK signaling pathway and 
PI3K-AKT signaling pathway. In addition, YQSX may exert its 
regulatory function in the pathogenesis of ITP and the regulation 
of pathways including proteoglycans in cancer, prostate cancer, 
glioma, and thyroid hormone and estrogen signaling pathways 
which are associated with the occurrence of ITP. MDM2, TP53, 
MAPK1, CDKN1A, MYC, and DDX5 were the key target gens 
in the gene network of YQSX for treatment of ITP. The network 
pharmacology appears to be a suitable approach for the study of 
complex TCM formulations.
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